Kirti Shila Sonkar, Ph.D., is a Principal Scientist and Team Leader at NemDx Inc. (USA); Qbiotix Developments Ltd. (UK), where she leads translational assay development for early detection of ALS, FTD, and Alzheimer’s disease. She received her Ph.D. in Biochemistry from Banaras Hindu University, India, and completed postdoctoral training in structural biology, molecular pathology, and virology at ICGEB New Delhi Trieste. Her research spans TR‑FRET assay development, immunoassay optimization, RNA–protein interaction mapping, and high‑yield protein engineering, integrating mechanistic biology with diagnostic innovation. She has solved more than ten PDB‑deposited protein structures, contributed to structural and functional studies of SARS‑CoV‑2 Mpro, MDHAR variants, and human CLIC1, and advanced understanding of TDP‑43 biology in neurodegeneration. Dr. Sonkar has secured over €500,000 in competitive international funding and received major honors, including the Arturo Falaschi Postdoctoral Fellowship, DHR Young Scientist Award, DBT Biocare Women Scientist Grant, ICMR Postdoctoral Fellowship, and Spiga di grano della Vitale Onlus Award. Her recent work includes developing a clinically validated hTR‑FRET assay for TDP‑43 functional activity, demonstrating diagnostic utility across multicenter ALS cohorts and supporting emerging biomarker pipelines.
Qbiotix Developments Ltd
Sandwich, UK